Related Experiment Videos
Efficacy of a low dose of cefotaxime in serious chest infections
J F Cade1, J Presneill, C Keighley
1Intensive Care Unit, Royal Melbourne Hospital, Victoria, Australia.
Abstract:
The optimal antibiotic dosage in serious chest infections is not established and commonly used regimens may well be excessive. We have compared the efficacy of a low dose of cefotaxime (2 g every 12 h) with a more usual dose (2 g every 8 h) in a prospective, randomized study of the treatment of chest infections in the seriously ill. Fifty intensive care unit patients received either regimen for five days. The two groups appeared demographically comparable. Clinical resolution occurred in 86 percent, no change occurred in 4 percent, and deterioration occurred in 10 percent. Microbiologic clearance occurred in 52 percent of those in whom a pathogen was isolated (46 percent of patients). There was no significant difference in clinical or microbiologic response between the two regimens. It is concluded that cefotaxime in a dose of 2 g twice daily is effective in the treatment of serious chest infections.
Insights
A low dose of cefotaxime (2g every 12 hours) is as effective as a higher dose for treating serious chest infections in critically ill patients. This finding suggests current antibiotic regimens may be excessive.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Pharmacology
Background:
- Optimal antibiotic dosing for severe chest infections remains undefined.
- Current treatment regimens may involve excessive antibiotic dosages.
Purpose of the Study:
- To compare the efficacy of a low-dose cefotaxime regimen (2 g every 12 hours) against a standard dose (2 g every 8 hours).
- To evaluate treatment outcomes in seriously ill patients with chest infections.
Main Methods:
- Prospective, randomized study involving 50 intensive care unit patients.
- Patients received either low-dose or standard-dose cefotaxime for five days.
- Demographic comparability between treatment groups was assessed.
Main Results:
- Clinical resolution observed in 86% of patients, with no significant difference between regimens.
- Microbiologic clearance occurred in 52% of patients with an identified pathogen.
- No significant differences in clinical or microbiologic response were noted between the low-dose and standard-dose groups.
Conclusions:
- Cefotaxime at a dose of 2 g twice daily demonstrates effectiveness in treating serious chest infections.
- Lower cefotaxime dosing may be sufficient for managing severe chest infections, potentially reducing antibiotic overuse.